These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Isoxazoles substituted with 4-pyridyl and o-chlorophenyl radicals]. Arena F; Manna F; Stein ML; Parente L Farmaco Sci; 1975 May; 30(5):380-90. PubMed ID: 1175763 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and antiproliferative activity in vitro of new 3-substituted aminoisoxazolo[5,4-b]pyridines. Poreba K; Wietrzyk J; Opolski A Acta Pol Pharm; 2003; 60(4):293-301. PubMed ID: 14714858 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological properties of 5-benzoylamino-3-methyl-4-isoxazolocarboxylic acid derivatives. Machoń Z; Ryng S Arch Immunol Ther Exp (Warsz); 1981; 29(6):813-21. PubMed ID: 7349102 [TBL] [Abstract][Full Text] [Related]
6. Synthesis of isoxazolo[5,4-b]pyridines by microwave-assisted multi-component reactions in water. Tu SJ; Zhang XH; Han ZG; Cao XD; Wu SS; Yan S; Hao WJ; Zhang G; Ma N J Comb Chem; 2009; 11(3):428-32. PubMed ID: 19364093 [TBL] [Abstract][Full Text] [Related]
7. [Synthesis and biological properties of isoxazolo[5,4-d]pyrimidine derivatives]. Machoń Z; Ryng S Acta Pol Pharm; 1984; 41(1):37-42. PubMed ID: 6496138 [No Abstract] [Full Text] [Related]
8. Potential biologically active agents. Note II. Synthesis and pharmacological evaluation of some new 3-isoxazolyl-substituted-1,2,3-benzotriazin-4(3H)-ones. Daidone G; Raffa D; Plescia S; Bajardi ML Boll Chim Farm; 1985 May; 124(5):201-6. PubMed ID: 4052241 [No Abstract] [Full Text] [Related]
9. [Research on heterocyclic compounds. VII. Heteroarylcarboxylic and 2-(heteroaryl)propionic acids]. Abignente E; Arena F; De Caprariis P; Parente L Farmaco Sci; 1977 Oct; 32(10):735-46. PubMed ID: 923787 [No Abstract] [Full Text] [Related]
10. [Research on heterocyclic compounds. I. Heteroarylacetic acids with anti-inflammatory action]. Abignente E; Arena F; de Caprariis P Farmaco Sci; 1975 Oct; 30(10):815-22. PubMed ID: 1183599 [TBL] [Abstract][Full Text] [Related]